EA
FPRX

Emerald Acquisition’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Emerald Acquisition’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$10.7M Sell
204,006
-27,548
-12% -$1.32M 0.02% 833
2016
Q2 		$9.57M Buy
+231,554
New +$10.1M 0.02% 953

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Emerald Acquisition's FPRX Position: Q3 2016 in Review

Emerald Acquisition reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 12% in Q3 2016, selling an estimated $1.32M and leaving 204,006 shares worth $10.7M. The position accounts for 0.02% of the portfolio, ranked #833.

Emerald Acquisition first reported a position in FPRX in Q2 2016 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

  • Emerald Acquisition held 204,006 shares of Five Prime Therapeutics, Inc. worth $10.7M as of Q3 2016.
  • Emerald Acquisition sold 27,548 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $1.32M.
  • Five Prime Therapeutics, Inc. made up 0.02% of Emerald Acquisition's portfolio in Q3 2016, its #833 holding.
  • Emerald Acquisition first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.